FLNA — Filana Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Affirm, Trump Media, Comstock
Cassava falls after failing in second late-stage trial
Cassava falls after stopping development of Alzheimer's drug
Cassava to discontinue development of Alzheimer's disease drug (updated)
Cassava to discontinue development of Alzheimer's disease drug
Brief: Cassava Sciences Provides A Business Update
Press Digest: New York Times business news - Nov 26
Cassava Sciences shares plummet as Alzheimer's drug fails in late-stage study
U.S. STOCKS ON THE MOVE-AMC, Alnylam, Super Micro
U.S. STOCKS ON THE MOVE-Replimune, Snowflake, Virpax Pharmaceuticals
Cassava Sciences shares drop as Alzheimer's drug fails in late-stage study
Cassava's Alzheimer's drug fails in late-stage study (updated)
Primary Endpoints
Cassava's Alzheimer's drug fails in late-stage study
Brief: Cassava Sciences Appoints Freda Nassif As Chief Commercial Officer
Cassava Sciences Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Cassava Sciences Q3 Basic EPS USD -0.58
Cassava Sciences Inc expected to post a loss of 88 cents a share - Earnings Preview
Cassava gains after SEC settlement on Alzheimer's drug trial claims